Over the next five years, well almost certainly have better human trials, clearer safety data and a much better understanding of where BPC-157 genuinely has a place in medicine and where it doesnt. That may ultimately prove to be the real story
Use cautiously in patients with angina, recent myocardial infarction (MI), cerebrovascular accident (CVA), and hepatic or renal disease (guanabenz and guanfacine)
The effects of peptide therapy vary from person to person
Histopathological findings revealed preservation of neural architecture, with reduced axonal degeneration, diminished neuronal loss, and limited formation of cystic cavities, suggesting an attenuation of secondary injury processes (12)
Avoid exposure to excessive heat, humidity, and direct sunlight
Lyophilisation removes water from the peptide during manufacture